350 related articles for article (PubMed ID: 10897209)
1. [Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU].
Shirasaka T; Yamamitsu S; Tsuji A; Terashima M; Hirata K
Gan To Kagaku Ryoho; 2000 Jun; 27(6):832-45. PubMed ID: 10897209
[TBL] [Abstract][Full Text] [Related]
2. Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU from bench to clinic.
Shirasaka T
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():193-205. PubMed ID: 10895155
[TBL] [Abstract][Full Text] [Related]
3. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
Shirasaka T; Tsukuda M; Inuyama Y; Taguchi T
Gan To Kagaku Ryoho; 2001 Jun; 28(6):855-64. PubMed ID: 11432358
[TBL] [Abstract][Full Text] [Related]
4. [Combination therapy of continuous venous infusion (CVI) of 5-FU and low dose consecutive cisplatin (CDDP), and the new oral anti-cancer drug S-1 for advanced gastro-intestinal cancer].
Shirasaka T; Aiba K; Araki H; Suzuki M; Terashima M; Mikami Y
Gan To Kagaku Ryoho; 1999 Mar; 26(4):456-66. PubMed ID: 10097742
[TBL] [Abstract][Full Text] [Related]
5. Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan.
Shirasaka T; Yamamitsu S; Tsuji A; Taguchi T
Invest New Drugs; 2000 Nov; 18(4):315-29. PubMed ID: 11081568
[TBL] [Abstract][Full Text] [Related]
6. [Timeline from discovery of 5-FU to development of an oral anticancer agent S-1 and its drug concept].
Shirasaka T; Taguchi T
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():4-18. PubMed ID: 16897967
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
[TBL] [Abstract][Full Text] [Related]
8. [Combination chemotherapy with 5-FU and CDDP or CDDP analog for head and neck cancer].
Fujii M; Ohno Y; Tokumaru Y; Imanishi Y; Kanke M
Gan To Kagaku Ryoho; 1996 Nov; 23(13):1740-6. PubMed ID: 8937483
[TBL] [Abstract][Full Text] [Related]
9. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Shirasaka T; Shimamoto Y; Kato T; Fukushima M
Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
[TBL] [Abstract][Full Text] [Related]
10. [Biochemical modulation of 5-FU--effect of low dose CDDP].
Hirata K; Yamamitsu S; Tsuji A; Shirasaka T; Mukaiya M; Oikawa I; Kimura H; Sasaki K; Denno R
Gan To Kagaku Ryoho; 1999 Mar; 26(4):467-75. PubMed ID: 10097743
[TBL] [Abstract][Full Text] [Related]
11. [A pilot study of low-dose TS-1 and cisplatin combination chemotherapy for advanced gastric cancer].
Kamata T; Hayashi Y; Minatoya G; Michiwa Y; Onishi I; Takeda T; Koyasaki N; Kanno M
Gan To Kagaku Ryoho; 2001 Oct; 28(10):1419-22. PubMed ID: 11681250
[TBL] [Abstract][Full Text] [Related]
12. [Combination therapy of a novel oral fluorouracil derivative TS-1 with low-dose cisplatin for recurrent and very advanced gastric cancer].
Nakata B; Hirakawa K
Gan To Kagaku Ryoho; 2004 Nov; 31(12):1962-8. PubMed ID: 15570921
[TBL] [Abstract][Full Text] [Related]
13. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Fukushima M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of a novel oral formation of 5-fluorouracil in combination with low-dose cisplatin as preoperative chemotherapy of oral squamous cell carcinoma.
Nakazawa M; Ohnishi T; Ohmae M; Chisoku H; Yui S; Iwai S; Sumi T; Fukuda Y; Kishino M; Yura Y
Int J Clin Pharmacol Res; 2005; 25(3):115-22. PubMed ID: 16366419
[TBL] [Abstract][Full Text] [Related]
15. [Combination chemotherapy of continuous infusion 5-FU and daily low-dose CDDP in colorectal carcinoma].
Furuhata T; Hirata K; Yamamitsu S; Kimura H; Sasaki K; Hata F; Shirasaka T
Gan To Kagaku Ryoho; 1999 Oct; 26(11):1554-8. PubMed ID: 10553412
[TBL] [Abstract][Full Text] [Related]
16. [Low-dose cisplatin added to continuous infusion of 5-fluorouracil or oral administration of UFT for inoperable advanced or recurrent colorectal cancer].
Asano M; Mori T; Takahashi K; Yasuno M
Gan To Kagaku Ryoho; 1997 Jan; 24(1):55-60. PubMed ID: 9020946
[TBL] [Abstract][Full Text] [Related]
17. [Clinical evaluation of S-1, a new anticancer agent, in patients with advanced gastrointestinal cancer. S-1 Cooperative Gastrointestinal Study Group].
Maehara Y; Sugimachi K; Kurihara M; Taguchi T
Gan To Kagaku Ryoho; 1999 Mar; 26(4):476-85. PubMed ID: 10097744
[TBL] [Abstract][Full Text] [Related]
18. Long-term administration of low-dose cisplatin plus 5-fluorouracil prolongs the postoperative survival of patients with esophageal cancer.
Shiozaki A; Yamagishi H; Itoi H; Fujiwara H; Kikuchi S; Okamoto K; Ichikawa D; Fuji N; Ochiai T; Sonoyama T; Ueda Y
Oncol Rep; 2005 Apr; 13(4):667-72. PubMed ID: 15756440
[TBL] [Abstract][Full Text] [Related]
19. [Three cases of advanced gastric cancer treated by TS-1 in combination with low-dose cisplatinum].
Gomi T; Ohtoshi M; Tamaki N; Momoi H; Kanaya S; Katayama T; Wada Y
Gan To Kagaku Ryoho; 2002 Feb; 29(2):301-4. PubMed ID: 11865638
[TBL] [Abstract][Full Text] [Related]
20. Intermittent FLDP: 24-h infusion of 5-FU on days 1, 3 and 5 combined with low-dose cisplatin on days 1-5 for gastric cancer, and its pharmacologic and kinetic rationale.
Terashima M; Irinoda T; Kawamura H; Takagane A; Abe K; Oyama K; Fujiwara H; Saito K; Gotoh M; Shirasaka T
Cancer Chemother Pharmacol; 2003 Mar; 51(3):240-6. PubMed ID: 12655443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
